# 通用药品合同制造市场 > 通用药品合同制造市场研究报告，按产品类型（药品原料药、制剂、胶囊、片剂、注射剂）、按制造工艺（化学合成、生物技术、无菌制造、固体剂型制造、液体制造）、按应用（通用药品、非处方药、生物类似药、合同制造）、按商业模式（全方位合同制造、半集成合同制造、基于产能的合同制造、按服务收费的合同制造）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 预测至2035年 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.18% - **2024:** $ 78.82 Billion - **2025:** $ 83.69 Billion - **2035:** $ 152.48 Billion - **Key Players:** Teva Pharmaceutical Industries Ltd (IL), Sandoz International GmbH (AT), Mylan N.V. (US), Amgen Inc (US), Fresenius Kabi AG (DE), Aurobindo Pharma Ltd (IN), Dr. Reddy's Laboratories Ltd (IN), Sun Pharmaceutical Industries Ltd (IN), Cipla Ltd (IN) **Report ID:** MRFR/Pharma/27866-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/generic-pharmaceuticals-contract-manufacturing-market-29591 --- ## Market Summary ## **Generic Pharmaceuticals Contract Manufacturing Market Overview** As per MRFR analysis, the Generic Pharmaceuticals Contract Manufacturing Market Size was estimated at 78.82 (USD Billion) in 2024. The Generic Pharmaceuticals Contract Manufacturing Market Industry is expected to grow from 83.69 (USD Billion) in 2025 to 143.60 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.18% during the forecast period (2025 - 2034). ### **Key Generic Pharmaceuticals Contract Manufacturing Market Trends Highlighted** The generic pharmaceutical contract manufacturing market is experiencing a surge in demand due to the increasing prevalence of chronic diseases and the expiration of patents for branded drugs. Additionally, the rising cost of healthcare and government initiatives to promote access to affordable medications are driving the growth of this market. Key market drivers include the expansion of emerging markets, the adoption of biosimilars, and the increasing demand for complex generic products. Opportunities to be explored or captured include the development of innovative manufacturing technologies, the expansion into new therapeutic areas, and the establishment of partnerships with pharmaceutical companies. Recent trends in the market include the integration of digital technologies, the focus on sustainability, and the growing importance of quality and regulatory compliance. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Generic Pharmaceuticals Contract Manufacturing Market Drivers** ### Increasing Demand for Generic Pharmaceuticals The rising cost of healthcare has led to an increased demand for generic pharmaceuticals. Generic drugs are just as effective as brand-name drugs, but they are significantly cheaper. This has made them a more attractive option for patients and healthcare providers alike. The growing demand for generic pharmaceuticals is expected to continue to drive the growth of the Generic Pharmaceuticals Contract Manufacturing Market. The Generic Pharmaceuticals Contract Manufacturing Market is expected to witness significant growth over the next decade. The market is projected to grow from USD 69.91 billion in 2023 to USD 120.0 billion by 2032, at a CAGR of 6.18%. The increasing demand for generic pharmaceuticals is one of the key factors driving the growth of the market. Generic pharmaceuticals are typically manufactured by contract manufacturing organizations (CMOs). CMOs provide a range of services to pharmaceutical companies, including drug development, manufacturing, and packaging. The use of CMOs allows pharmaceutical companies to focus on their core competencies and reduce their operating costs. The growing number of CMOs is also expected to contribute to the growth of the Generic Pharmaceuticals Contract Manufacturing Market. In addition to the increasing demand for generic pharmaceuticals, the rising cost of drug development is also driving the growth of the Generic Pharmaceuticals Contract Manufacturing Market. The cost of developing a new drug can exceed USD 1 billion. This has made it increasingly difficult for pharmaceutical companies to develop new drugs. As a result, pharmaceutical companies are increasingly turning to CMOs to help them develop and manufacture their drugs. The Generic Pharmaceuticals Contract Manufacturing Market is a highly competitive market. The key players in the market include Lonza Catalent Patheon Thermo Fisher Scientific Samsung Biologics. These companies offer a range of services to pharmaceutical companies, including drug development, manufacturing, and packaging. The competitive landscape of the market is expected to remain fragmented over the next decade. ### Technological Advancements Technological advancements are also playing a key role in the growth of the Generic Pharmaceuticals Contract Manufacturing Market. The development of new technologies is making it possible to produce generic drugs more efficiently and cost-effectively. For example, the use of continuous manufacturing is reducing the time and cost of drug production. The development of new drug delivery systems is also making it possible to deliver generic drugs in a more targeted and effective manner. The increasing adoption of new technologies is expected to continue to drive the growth of the Generic Pharmaceuticals Contract Manufacturing Market. CMOs are investing in new technologies to improve their efficiency and productivity. This is expected to lead to lower costs and shorter lead times for the production of generic drugs. The development of new technologies is also expected to lead to the development of new generic drugs. CMOs are working with pharmaceutical companies to develop new generic drugs that are more effective and affordable. This is expected to further drive the growth of the Generic Pharmaceuticals Contract Manufacturing Market. ### Government Regulations Government regulations are also playing a role in the growth of the Generic Pharmaceuticals Contract Manufacturing Market. Governments are increasingly implementing policies to promote the use of generic drugs. For example, the US government has implemented a number of policies to increase the availability and affordability of generic drugs. These policies have helped to drive the growth of the Generic Pharmaceuticals Contract Manufacturing Market. Governments are also implementing policies to regulate the manufacture of generic drugs. These policies are designed to ensure that generic drugs are safe and effective. The implementation of these policies is expected to continue to drive the growth of the Generic Pharmaceuticals Contract Manufacturing Market. ## **Generic Pharmaceuticals Contract Manufacturing Market Segment Insights** ### **Generic Pharmaceuticals Contract Manufacturing Market Product Type Insights** The Generic Pharmaceuticals Contract Manufacturing Market is segmented by product type into Pharmaceutical APIs, Formulations, Capsules, Tablets, and Injectables. Among these, the Formulation segment held the largest market share in 2023 and is expected to continue its dominance throughout the forecast period. The growth of this segment can be attributed to the increasing demand for generic drugs and the rising popularity of outsourcing pharmaceutical manufacturing. The Pharmaceutical APIs segment is also expected to witness significant growth during the forecast period due to the increasing demand for active pharmaceutical ingredients (APIs) from generic drug manufacturers. The growing adoption of biosimilars is also expected to contribute to the growth of this segment. The Capsules segment is another major segment in the Generic Pharmaceuticals Contract Manufacturing Market. The growth of this segment can be attributed to the increasing demand for oral solid dosage forms. The rising popularity of modified-release capsules is also expected to contribute to the growth of this segment. The Tablets segment is also expected to witness significant growth during the forecast period. The growth of this segment can be attributed to the increasing demand for generic tablets. The rising popularity of chewable and sublingual tablets is also expected to contribute to the growth of this segment. The Injectables segment is expected to witness moderate growth during the forecast period. The growth of this segment can be attributed to the increasing demand for generic injectables. The rising popularity of self-injectable drugs is also expected to contribute to the growth of this segment. Overall, the Generic Pharmaceuticals Contract Manufacturing Market is expected to witness significant growth during the forecast period. The growth of the market can be attributed to the increasing demand for generic drugs, the rising popularity of outsourcing pharmaceutical manufacturing, and the growing adoption of biosimilars. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Generic Pharmaceuticals Contract Manufacturing Market Manufacturing Process Insights** The Generic Pharmaceuticals Contract Manufacturing Market is segmented by Manufacturing Process into Chemical Synthesis, Biotechnology, Sterile Manufacturing, Solid Dose Manufacturing, and Liquid Manufacturing. Among these segments, Chemical Synthesis held the largest market share of 38.4% in 2023. The Chemical Synthesis segment is expected to continue to dominate the market during the forecast period, owing to the increasing demand for generic drugs and the cost-effectiveness of chemical synthesis compared to other manufacturing processes. The Biotechnology segment is expected to exhibit the highest CAGR of 7.2% during the forecast period due to the growing demand for biosimilars and the increasing adoption of biotechnology for the production of complex generic drugs. ### **Generic Pharmaceuticals Contract Manufacturing Market Application Insights** The application segment of the Generic Pharmaceuticals Contract Manufacturing Market is classified into Generic Pharmaceuticals, Over-the-Counter Drugs, Biosimilars, and Contract Manufacturing. Among these, Generic Pharmaceuticals holds the largest market share and is projected to continue its dominance throughout the forecast period. The increasing demand for affordable healthcare solutions, coupled with the growing prevalence of chronic diseases, is driving the growth of this segment. Over-the-counter drugs and Biosimilars are also anticipated to witness significant growth in the coming years due to the rising awareness about self-medication and the increasing adoption of biologics. Contract Manufacturing is expected to contribute substantially to the market growth as pharmaceutical companies outsource their manufacturing processes to reduce costs and focus on core competencies. ### **Generic Pharmaceuticals Contract Manufacturing Market Business Model Insights** The Generic Pharmaceuticals Contract Manufacturing Market is segmented based on the Business Model into Full-Service Contract Manufacturing, Semi-Integrated Contract Manufacturing, Capacity-Based Contract Manufacturing, and Fee-for-Service Contract Manufacturing. Among these, the Full-Service Contract Manufacturing segment held the largest market share in 2023 and is expected to continue its dominance throughout the forecast period. This is attributed to the comprehensive services offered by full-service contract manufacturers, including product development, manufacturing, packaging, and distribution. Additionally, the growing demand for outsourcing non-core activities by pharmaceutical companies is driving the growth of this segment. The Fee-for-Service Contract Manufacturing segment is expected to witness the highest growth rate during the forecast period due to its flexibility and cost-effectiveness. ### **Generic Pharmaceuticals Contract Manufacturing Market Regional Insights** The regional market segments exhibit diverse growth patterns in the Generic Pharmaceuticals Contract Manufacturing Market. North America held the largest revenue share in 2023 and is expected to maintain its dominance throughout the forecast period. The growth in this region can be attributed to the presence of major pharmaceutical companies and contract manufacturers, as well as favorable government regulations. Europe is the second-largest market, driven by strong demand for generic pharmaceuticals in countries such as Germany, France, and the United Kingdom. The APAC region is projected to witness significant growth over the next decade, fueled by increasing healthcare expenditure and rising demand for affordable generic drugs in emerging economies like India and China. South America and MEA are expected to experience steady growth, driven by expanding healthcare infrastructure and government initiatives to improve access to affordable medicines. These insights can assist market players in tailoring their strategies to target specific regional markets and capitalize on growth opportunities. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Generic Pharmaceuticals Contract Manufacturing Market Key Players and Competitive Insights** In the competitive Generic Pharmaceuticals Contract Manufacturing Market, leading players are constantly innovating and expanding their offerings to gain market share. Contract manufacturers such as Piramal Pharma Solutions, Jubilant HollisterStier, and Hetero Labs are investing heavily in research and development to create new and improved generic pharmaceuticals. They are also expanding their geographical reach through acquisitions and partnerships to cater to the growing demand for generic drugs in emerging markets. One of the leading players in the Generic Pharmaceuticals Contract Manufacturing Market is Piramal Pharma Solutions. The company has a strong track record of delivering high-quality generic drugs to its customers and is known for its expertise in complex generic formulations. Piramal Pharma Solutions has a global presence with manufacturing facilities in North America, Europe, and Asia. The company's focus on innovation and customer service has helped it to become a trusted partner for many generic pharmaceutical companies. A major competitor in the Generic Pharmaceuticals Contract Manufacturing Market is Hetero Labs. The company is one of the largest manufacturers of generic drugs in India and has a growing presence in international markets. Hetero Labs is known for its low-cost manufacturing capabilities and its ability to produce high-quality generic drugs. The company has a strong pipeline of new generic products and is investing heavily in research and development to expand its product portfolio. ### **Key Companies in the Generic Pharmaceuticals Contract Manufacturing Market Include** ## **Generic Pharmaceuticals Contract Manufacturing Market Developments** The growth of the market is attributed to the increasing demand for generic drugs, the rising prevalence of chronic diseases, and the growing adoption of outsourcing by pharmaceutical companies. ### Recent news developments in the market include - In February 2023, Lonza announced the expansion of its biologics manufacturing facility in Visp, Switzerland, to meet the growing demand for generic biologics. - In March 2023, Catalent acquired Micron Technologies, a leading provider of clinical trial services, to enhance its drug development capabilities. - In April 2023, Thermo Fisher Scientific launched a new bioproduction facility in Singapore to support the production of generic vaccines and antibody-based therapies. ## **Generic Pharmaceuticals Contract Manufacturing Market Segmentation Insights** ### **Generic Pharmaceuticals Contract Manufacturing Market Product Type Outlook** ### **Generic Pharmaceuticals Contract Manufacturing Market Manufacturing Process Outlook** ### **Generic Pharmaceuticals Contract Manufacturing Market Application Outlook** ### **Generic Pharmaceuticals Contract Manufacturing Market Business Model Outlook** ### **Generic Pharmaceuticals Contract Manufacturing Market Regional Outlook** ## Market Drivers ### 增加医疗支出 各地区不断上升的医疗支出似乎是通用药品合同制造市场的一个关键驱动因素。随着政府和私营部门向医疗保健分配更多资金，对经济实惠药物的需求也在加剧。这一趋势在新兴经济体中尤为明显，医疗预算正在扩大，以改善对基本药物的获取。根据最近的数据，医疗支出预计在未来几年将以约5.4%的复合年增长率增长。这一支出的增加可能会促进合同制造行业的发展，因为制药公司寻求外包生产以满足对仿制药日益增长的需求。因此，通用药品合同制造市场有望实现显著增长，因为它与提高医疗可及性的总体目标相一致。 ### 仿制药的监管支持 有利于仿制药生产和分销的监管框架显著影响了仿制药合同制造市场。全球各国政府越来越认识到仿制药在降低医疗成本和改善患者用药可及性方面的重要性。加快仿制药配方审批流程和对制造商的激励措施等举措变得越来越普遍。例如，鼓励使用仿制药的政策的推出，导致其市场份额显著增加，在某些地区，仿制药占处方的90%以上。这种监管支持不仅增强了仿制药制造商的竞争力，还刺激了合同制造部门，因为制药公司希望利用有利的条件。因此，仿制药合同制造市场在这些支持性监管环境下可能会蓬勃发展。 ### 日益关注可持续性 制药行业对可持续性日益重视，成为了仿制药合同制造市场的一个显著驱动因素。随着环境问题的日益突出，制药公司越来越多地寻求在其运营中采用可持续的做法。这包括使用环保材料、减少废物的策略以及节能的制造过程。数据显示，实施可持续做法的公司可以增强其市场竞争力，并吸引环保意识强的消费者。此外，优先考虑可持续性的合同制造商可能会吸引更多的合作伙伴，因为制药公司希望与那些共享环境责任承诺的供应商对接。因此，仿制药合同制造市场可能会根据这些可持续性趋势而发展，促进该行业的创新与合作。 ### 日益增长的老龄化人口 人口老龄化的趋势是通用药品合同制造市场的重要驱动因素。随着全球人口的老龄化，慢性疾病的流行和对长期药物管理的需求增加。这一人口趋势预计将导致药品消费的增加，特别是通用药品，因为它们通常是品牌药物的更实惠替代品。数据显示，到2030年，60岁及以上的人口将超过10亿，这将导致对经济实惠的医疗解决方案的需求增加。因此，制药公司可能会将生产外包给合同制造商，以有效满足这一日益增长的需求。通用药品合同制造市场将从这一人口趋势中受益，因为它与可持续和可及的医疗解决方案的需求相一致。 ### 生物制剂和生物仿制药的扩展 生物制剂和生物仿制药的扩展正在成为仿制药合同制造市场的重要驱动力。随着生物制剂市场的持续增长，对生物仿制药的需求也在上升，生物仿制药本质上是生物药物的仿制版本。这一趋势得到了越来越多的生物药物失去专利保护的支持，为制造商提供了生产生物仿制药的机会。预计到2025年，生物仿制药市场将达到约1000亿美元，显示出巨大的增长潜力。制药公司可能会寻求合同制造服务，以应对生物制剂生产的复杂性，这通常需要专业的知识和技术。因此，仿制药合同制造市场预计将经历显著增长，因为它适应生物制剂和生物仿制药不断变化的格局。 ## Future Outlook 通用药品合同制造市场预计将在2024年至2035年间以6.18%的年复合增长率增长，推动因素包括对成本效益药物的需求增加和技术进步。 **New opportunities:** - 进入新兴市场，提供量身定制的仿制药解决方案。 到2035年，市场预计将巩固其作为成本效益高的制药解决方案领导者的地位。 ## Segment Insights ### 按产品类型：制剂（最大）与注射剂（增长最快） 在通用药品合同制造市场中，产品类型细分显示出竞争激烈的格局，制剂因其广泛的应用和需求占据了最大的市场份额。紧随其后的是片剂和胶囊，它们也占有显著的份额，而注射剂则迅速崛起，作为各种疗法中首选的给药方式引起了关注。制药原料药在这个生态系统中是基础，因为它们是这些制剂和给药方式的构建块。 配方（主导）与注射剂（新兴） 配方目前是通用药品合同制造市场的主导力量，主要由于其多功能性以及对满足各种治疗需求的复杂配方日益增长的需求。这些配方通常经过严格的质量评估和监管审查，确保其可靠性和有效性。另一方面，注射剂被认为是增长最快的细分市场，推动因素是慢性疾病的发病率上升，这些疾病需要密集的治疗方案。注射剂提供了更高的生物利用度和更快的治疗效果，使其在急性护理和专科药物中越来越受到青睐。因此，市场动态正在发生变化，倾向于创新和量身定制的药物递送方法。 ### 按制造工艺：化学合成（最大）与生物技术（增长最快） 在通用药品合同制造市场中，制造过程细分主要由化学合成主导，因其在生产广泛的仿制药方面的广泛应用而占据最大份额。化学合成因其成本效益和效率，仍然是许多制造商的首选方法，使其成为药物生产领域的主流。相比之下，生物技术细分正在迅速崛起，随着生物制药的进步而获得关注。随着越来越多的公司转向生物制剂，生物技术的市场存在显著增加，使其成为能够满足不断变化的医疗需求的关键参与者。 化学合成（主导）与生物技术（新兴） 化学合成以其在仿制药制造中的传统实践为特征，利用既定的化学工艺进行药物配方。这种方法在可扩展性和可靠性方面表现出色，为仿制药生产提供了稳定的基础。另一方面，生物技术提供了创新的药物开发方法，专注于活体系统和生物过程。其崛起反映了制药行业向更复杂疗法的转变，包括生物制剂和生物类似药，吸引了越来越多需要专业治疗的患者群体。这两种过程共同代表了仿制药市场中截然不同但至关重要的路径。 ### 按应用：通用药物（最大）与生物仿制药（增长最快） 在仿制药合同制造市场中，应用细分揭示了市场份额分布的有趣见解。仿制药在市场中占据主导地位，反映出其在消费者和医疗服务提供者中建立了良好的存在感和广泛的接受度。非处方药紧随其后，迎合了消费者自我用药的趋势。生物类似药虽然市场份额较小，但随着医疗行业越来越多地寻求成本效益高的替代昂贵生物制剂，正在迅速获得关注，展示了它们在制药领域日益增长的重要性。 通用药品（主导）与生物仿制药（新兴） 仿制药因其长期建立的生产流程和在全球市场的广泛可用性而主导市场。它们涵盖了广泛的治疗领域，确保满足不同患者的需求。相比之下，生物仿制药作为关键参与者正在崛起，受到监管激励和医疗专业人士日益增长的接受度的推动。虽然它们目前的市场份额较小，但其特点是先进的制造技术和生物等效性流程，为生物衍生药物提供了更实惠的选择。由于对降低医疗成本和增加药物可及性的需求，其接受度正在上升，预示着未来几年的显著增长潜力。 ### 按商业模式：全方位合同制造（最大）与按服务收费的合同制造（增长最快） 通用制药合同制造市场多样化，全面服务合同制造目前占据最大市场份额，因为其提供的服务涵盖整个生产周期。该细分市场受益于与客户建立的良好关系，以及高效处理大规模生产需求的能力。相比之下，按服务收费的合同制造虽然市场份额较小，但由于其灵活和量身定制的解决方案，正在迅速获得关注，这些方案吸引了寻求特定服务而不想长期承诺的公司。 合同制造：全方位服务（主导）与按服务收费（新兴） 全方位合同制造在仿制药行业中脱颖而出，成为主导模式，提供从开发到市场发布的端到端解决方案。该领域的特点在于其管理复杂制造过程的能力，通常整合各种服务，如配方开发和合规性。相比之下，按服务收费的合同制造是一种新兴模式，提供灵活性和较低的承诺水平，允许客户针对特定项目进行合作。这种模式对需要专业制造能力但缺乏全方位协议规模的小型公司或初创企业尤其具有吸引力。 ## Regional Market Share Analysis ### 北美：制药创新领袖 北美在仿制药合同制造市场中占据主导地位，约占全球市场份额的45%。该地区受益于强大的医疗基础设施、对经济实惠药物的日益需求以及有利的监管框架。慢性疾病的增加和老龄化人口进一步推动市场增长，研发和制造能力的重大投资也在其中。美国是最大的市场，其次是加拿大，两者都展示了以Teva制药工业和Mylan N.V.等主要参与者为特征的竞争格局。先进技术和严格的质量标准增强了该地区在合同制造方面的吸引力。公司越来越注重战略合作伙伴关系，以扩大市场覆盖面并提高运营效率。 ### 欧洲：监管框架加强市场 欧洲在仿制药合同制造市场中是一个重要参与者，约占全球市场份额的30%。该地区的增长受到严格的监管标准、不断上升的医疗成本和对仿制药需求增加的推动。欧洲药品管理局（EMA）在确保合规性和促进创新方面发挥着关键作用，从而增强市场动态并吸引投资。主要国家包括德国、法国和英国，竞争格局中有Sandoz国际和Fresenius Kabi等主要参与者。成熟的制药行业和对可持续性的关注进一步巩固了该地区的市场地位。公司正在利用先进技术来简化生产流程，以满足对高质量仿制药日益增长的需求。 ### 亚太地区：新兴市场潜力 亚太地区正在迅速崛起为仿制药合同制造市场的关键参与者，约占全球市场份额的20%。该地区的增长受到医疗支出增加、庞大的人口基础和对经济实惠药物需求上升的推动。印度和中国等国处于前沿，受益于有利的政府政策和对制造能力的投资。印度是仿制药生产的主要中心，Aurobindo Pharma和Dr. Reddy's Laboratories等公司在其中发挥着重要作用。竞争格局由本地和国际参与者的混合构成，所有参与者都在努力提升市场存在感。该地区对创新和质量保证的关注预计将在未来几年推动进一步增长，使其成为合同制造的有吸引力的目的地。 ### 中东和非洲：未开发的市场机会 中东和非洲地区在仿制药合同制造市场中逐渐获得关注，约占全球市场份额的5%。增长受到医疗需求增加、制药行业投资上升和对本地制造能力日益关注的推动。各国政府正在实施政策以提高医疗服务的可及性，预计这将在未来几年推动市场动态。南非和阿联酋等国处于领先地位，竞争格局中包括本地和国际参与者。关键公司的存在正在增长，强烈强调合作伙伴关系和协作以增强生产能力。该地区的增长潜力显著，正在努力建立自己作为仿制药制造中心的地位。 ## Competitive Benchmarking 通用药品合同制造市场目前的特点是动态竞争格局，受诸如对经济实惠药物的需求增加、监管变化以及药物开发中持续推动创新等因素的驱动。像以色列的Teva制药工业有限公司、奥地利的Sandoz国际有限公司和美国的Mylan N.V.等主要参与者，战略性地利用其广泛的制造能力和全球影响力。Teva（以色列）专注于扩大其生物仿制药组合，而Sandoz（奥地利）则强调其在制造过程中对可持续性和数字化转型的承诺。Mylan（美国）积极寻求合作伙伴关系，以增强其产品供应，这共同塑造了一个越来越注重创新和运营效率的竞争环境。 在商业策略方面，公司正在本地化制造，以降低成本并提高供应链的韧性。市场似乎适度分散，多个参与者争夺市场份额，但主要公司的集体影响力仍然显著。这种竞争结构允许提供多样化的产品和服务，以满足各种地区需求和监管要求。 2025年8月，Teva制药工业有限公司（以色列）宣布与一家领先的生物技术公司建立战略合作伙伴关系，共同开发一系列新的生物仿制药。这一合作预计将增强Teva在生物仿制药市场的地位，该市场预计在未来几年将显著增长。该合作不仅使Teva的产品组合多样化，还与全球向更经济实惠的生物治疗药物的趋势相一致。 2025年9月，Sandoz国际有限公司（奥地利）推出了一项新举措，旨在减少其制造设施的碳足迹。这一举措强调了Sandoz对可持续性的承诺，并使公司在环保意识强的利益相关者中处于有利地位。通过将可持续实践融入其运营，Sandoz可能会提升其品牌声誉，并吸引那些优先考虑环保产品的新客户。 2025年10月，Mylan N.V.（美国）通过收购一家位于欧洲的先进设施扩大了其制造能力。这一收购具有战略重要性，因为它不仅增加了Mylan的生产能力，还增强了其满足欧洲市场对通用药物日益增长的需求的能力。该设施预计将简化运营并提高供应链效率，进一步巩固Mylan的竞争优势。 截至2025年10月，通用药品合同制造市场的竞争趋势越来越受到数字化、可持续性和人工智能在制造过程中的整合的定义。战略联盟变得越来越普遍，使公司能够汇聚资源和专业知识以推动创新。展望未来，竞争差异化可能会从传统的基于价格的竞争转向关注技术进步、供应链可靠性和创新产品供应，反映出行业向价值驱动策略的更广泛转变。 ## Recent News & Developments 市场的增长归因于对仿制药的需求增加、慢性疾病的流行率上升以及制药公司外包的日益普及。 ### 市场的最新新闻动态包括 - 2023年2月，Lonza宣布在瑞士维斯普扩建其生物制药生产设施，以满足对仿制生物药日益增长的需求。 - 2023年3月，Catalent收购了临床试验服务的领先提供商Micron Technologies，以增强其药物开发能力。 - 2023年4月，Thermo Fisher Scientific在新加坡推出了一座新的生物生产设施，以支持仿制疫苗和抗体治疗的生产。 ## Report Scope | 2024年市场规模 | 78.82（十亿美元） | | --- | --- | | 2025年市场规模 | 83.69（十亿美元） | | 2035年市场规模 | 152.48（十亿美元） | | 复合年增长率（CAGR） | 6.18%（2024 - 2035） | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 十亿美元 | | 主要公司简介 | 市场分析进行中 | | 覆盖的细分市场 | 市场细分分析进行中 | | 主要市场机会 | 先进制造技术的采用提高了仿制药合同生产市场的效率。 | | 主要市场动态 | 对成本效益药物生产的需求上升推动了仿制药合同生产市场的整合和创新。 | | 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 | ## Frequently Asked Questions **Q: 到2035年，仿制药合同制造市场的预计市场估值是多少？** A: 预计到2035年，通用药品合同制造市场的市场估值为1524.8亿美元。 **Q: 2024年通用药品合同制造市场的整体市场估值是多少？** A: 2024年，通用药品合同制造市场的整体市场估值为788.2亿美元。 **Q: 2025年至2035年，仿制药合同制造市场的预期CAGR是多少？** A: 在2025年至2035年的预测期内，仿制药合同制造市场的预期CAGR为6.18%。 **Q: 在仿制药合同制造市场中，哪些公司被视为关键参与者？** A: 市场上的主要参与者包括Teva制药工业有限公司、Sandoz国际有限公司、Mylan N.V.等。 **Q: 在通用药品合同制造市场中，主要的产品类型有哪些？** A: 主要产品类型包括药物原料药、制剂、胶囊、片剂和注射剂。 **Q: 在仿制药合同制造市场中，平板电脑细分市场的估值范围是多少？** A: 平板电脑部门的估值范围预计在180亿到350亿美元之间。 **Q: 全方位合同制造部门在市场估值方面表现如何？** A: 全方位合同制造部门的估值在300亿到600亿美元之间。 **Q: 通用药品合同制造市场包括哪些制造过程？** A: 制造过程包括化学合成、生物技术、无菌制造、固体剂型制造和液体制造。 **Q: 合同制造应用细分市场的估值范围是多少？** A: 合同制造应用领域的估值范围在138.2亿到224.8亿美元之间。 **Q: 在通用药品合同制造市场中有哪些不同的商业模式？** A: 不同的商业模式包括全方位合同制造、半集成合同制造、基于产能的合同制造和按服务收费的合同制造。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/generic-pharmaceuticals-contract-manufacturing-market-29591*